- Home
- NEWT vs NPCE Comparison
NEWT vs NPCE Comparison
Compare NEWT & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- NPCE
- Stock Information
- Founded
- NEWT 1998
- NPCE 1997
- Country
- NEWT United States
- NPCE United States
- Employees
- NEWT N/A
- NPCE N/A
- Industry
- NEWT Major Banks
- NPCE Medical Specialities
- Sector
- NEWT Finance
- NPCE Health Care
- Exchange
- NEWT Nasdaq
- NPCE Nasdaq
- Market Cap
- NEWT 300.3M
- NPCE 328.8M
- IPO Year
- NEWT N/A
- NPCE 2021
- Fundamental
- Price
- NEWT $10.26
- NPCE $13.42
- Analyst Decision
- NEWT Hold
- NPCE Strong Buy
- Analyst Count
- NEWT 4
- NPCE 7
- Target Price
- NEWT $13.25
- NPCE $17.00
- AVG Volume (30 Days)
- NEWT 222.7K
- NPCE 226.3K
- Earning Date
- NEWT 10-29-2025
- NPCE 11-04-2025
- Dividend Yield
- NEWT 7.47%
- NPCE N/A
- EPS Growth
- NEWT 32.88
- NPCE N/A
- EPS
- NEWT 2.23
- NPCE N/A
- Revenue
- NEWT $380,364,000.00
- NPCE $94,864,000.00
- Revenue This Year
- NEWT N/A
- NPCE $22.13
- Revenue Next Year
- NEWT $12.56
- NPCE $6.07
- P/E Ratio
- NEWT $4.56
- NPCE N/A
- Revenue Growth
- NEWT 20.21
- NPCE 24.08
- 52 Week Low
- NEWT $9.12
- NPCE $6.63
- 52 Week High
- NEWT $15.41
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- NEWT 39.01
- NPCE 71.95
- Support Level
- NEWT $10.07
- NPCE $12.52
- Resistance Level
- NEWT $10.36
- NPCE $13.78
- Average True Range (ATR)
- NEWT 0.39
- NPCE 0.68
- MACD
- NEWT -0.00
- NPCE 0.34
- Stochastic Oscillator
- NEWT 17.61
- NPCE 92.38
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.